Is Esperion Therapeutics, Inc. overvalued or undervalued?

As of 8 May 2019, Esperion Therapeutics, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company appears to be overvalued given its current financial metrics. Key ratios include a Price to Book Value of -0.57, an EV to EBIT of -18.06, and an EV to EBITDA of -18.10, indicating significant financial distress and inefficiencies.
In comparison to its peers, Esperion's valuation is notably poor; for instance, Mind Medicine (MindMed), Inc. has an EV to EBITDA of -2.78, while Protalix Biotherapeutics, Inc. is classified as attractive with a P/E ratio of 27.91. The stark contrast in these metrics suggests that Esperion is not only underperforming relative to its peers but also indicates a lack of investor confidence. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -52.73%, reinforcing the notion that it is overvalued in the current market context.